The rodent transient receptor potential ankyrin-1 (TRPA1) channel has been hypothesized to serve as a temperature sensor for thermoregulation in the cold. We tested this hypothesis by using deletion of the Trpa1 gene in mice and pharmacological blockade of the TRPA1 channel in rats. In both Trpa1 Ϫ/Ϫ and Trpa1 ϩ/ϩ mice, severe cold exposure (8°C) resulted in decreases of skin and deep body temperatures to ϳ8°C and 13°C, respectively, both temperatures being below the reported 17°C threshold temperature for TRPA1 activation.
Introduction
Among transient receptor potential (TRP) channels, the cation channel TRP ankyrin-1 (TRPA1, formerly known as ANKTM1) is unique in that, despite the tremendous amount of research, it is still not clear whether and how it is activated by temperature (Bang and Hwang, 2009; Caspani and Heppenstall, 2009; Kwan and Corey, 2009; Nilius et al., 2012) . Since the first demonstration of cold sensitivity of TRPA1 by Story et al. (2003) , many in vitro and in vivo studies have supported the notion that TRPA1 is involved in the sensation of noxious cold (Viswanath et al., 2003; Bandell et al., 2004; Kwan et al., 2006; Klionsky et al., 2007; Fajardo et al., 2008; Andersson et al., 2009; Karashima et al., 2009; del Camino et al., 2010) . However, many other studies, both in vitro and in vivo, have contradicted this notion (Jordt et al., 2004; Nagata et al., 2005; Kwan et al., 2009; Knowlton et al., 2010; del Camino et al., 2010; Chen et al., 2011; Cordero-Morales et al., 2011) . Further complicating the issue, some TRPA1 orthologs (e.g., in pit-bearing snakes and insects) are activated by warmth, rather than cold (Viswanath et al., 2003; Hamada et al., 2008; Kwon et al., 2008; Gracheva et al., 2010) . With some exceptions (Chen et al., 2011) , most studies in mammals have focused on the role of TRPA1 in nocifensive behaviors, which is not surprising because the low threshold temperature for activation of this channel in vitro (Ͻ 17°C, according to Story et al., 2003; or somewhere between 11°C and 25°C, according to Klionsky et al., 2007 ) is close to the threshold temperature for pain responses in humans (Davis and Pope, 2002) .
The question of whether peripheral TRPA1 channels can serve as cold sensors for the thermoregulation system was previously touched upon in two studies Chen et al., 2011) , but no definitive answer was obtained. The first study showed that deletion of the Trpa1 gene in mice did not lower their selected ambient temperature (T a ), thus suggesting that TRPA1 is not involved in the control of thermopreferendum. However, these mice were not subjected to any prolonged cold exposure that might have been required for TRPA1 activation. Furthermore, deep body temperature (T b ) was not measured in the Trpa1 Ϫ/Ϫ mice; if it was decreased, signals from deep-tissue thermosensors (other than TRPA1) could have compensated for the lack of TRPA1-mediated cold signals from the skin. The second study (Chen et al., 2011) showed that A967079, a potent and selective TRPA1 antagonist, did not affect the deep T b in rats at near-thermoneutral conditions (i.e., at temperatures substantially higher than those required for TRPA1 activation). The effects of A967079 in the cold (when TRPA1 channels may be activated) were not investigated. In the present study, we studied the effects of genetic deletion and pharmacological blockade of TRPA1 on the deep T b and thermoeffector activities in mice and rats exposed to deep cold.
Materials and Methods

Animals. Breeding pairs of Trpa1
ϩ/Ϫ mice were donated to the University of Pecs by Dr. Pierangelo Geppetti. The mice came from the University of Florence colony, which in turn originated from the colony of the University of California, San Francisco . At the University of Pecs, the first-generation offsprings of the donated Trpa1 ϩ/Ϫ mice were genotyped by PCR analysis (Knowlton et al., 2010 ) and bred as separate wild-type (Trpa1 ϩ/ϩ ) and homozygous genedeleted (Trpa1 Ϫ/Ϫ ) lines. Fourteen mice of both sexes representing the first two generations of each line were used in Experiment 1 (also at the University of Pecs). At the time of experiments, the mice weighed 22-27 g. Forty male Sprague Dawley rats (Harlan) weighing 220 -300 g were housed and used in Experiment 2 at Amgen. Sixty male Wistar rats (Harlan) weighing 150 -250 g were housed and used in Experiment 3 at St. Joseph's Hospital and Medical Center. At all three centers, animals were housed in temperature-controlled rooms on a 12/12 h light/dark cycle. Standard rodent chow and tap water were available ad libitum. For thermophysiological experiments (Experiments 1 and 3), mice and rats were extensively habituated to staying inside wire-mesh cylindrical confiners as described previously (Romanovsky et al., 2002; Garami et al., 2011) . All procedures conducted at each center were approved by the Institutional Animal Use and Care Committee of the University of Pecs, Amgen, or St. Joseph's Hospital and Medical Center, respectively.
Drugs. The TRPA1 antagonist compound 43 ((4 R) -1,2,3,4-tetrahydro-4-[3-(3-methoxypropoxy) phenyl]-2-thioxo-5H-indeno[1,2-d]pyrimidin-5-one) and its inactive (left) enantiomer compound 44 were synthesized by Amgen as enantiopure compounds using the Gijsen et al. (2012) method with modifications. The TRPA1 antagonist A967079 ((1 E,3E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-one oxime), reported by Chen et al. (2011) , was synthesized by AbbVie. The TRP melastatin-8 (TRPM8) channel antagonist AMG2850 (( R)-8-[4-(trifluoromethyl) phenyl]-N- [( S)-1,1,1-trifluoropropan-2-yl]-5,6-dihydro-1,7-naphthyridine-7-(8 H)-carboxamide) , recently reported by , was synthesized by Amgen. For intragastric (i.g.) gavage, all compounds were suspended in the vehicle (Amgen) containing 2% HPMC and 1% Tween 80 at pH 2.2 (adjusted with methanesulfonic acid). The vehicle or suspension of compound 43 (1-10 mg/ml), compound 44 (10 mg/ml), A967079 (3 mg/ml), or AMG2850 (3 mg/ml) was administered (10 ml/ kg, i.g.) using disposable soft feeding needles. The doses delivered were as follows: 10 -100 mg/kg (compound 43), 100 mg/kg (compound 44), 30 mg/kg (A967079), and 30 mg/kg (AMG2850). Ca 2ϩ uptake. Chinese hamster oocyte lines expressing rat TRPA1 were generated in tetracycline-inducible TREx expression system (Invitrogen) (Klionsky et al., 2007) . Cells (3.0 ϫ 10 4 per well) were seeded in Cytostar 96-well plates (PerkinElmer) and exposed to tetracycline (0.5 g/ml). One day later, allyl isothiocyanate (AITC)-or cold-induced TRPA1 activation was measured as cellular uptake of 45 Ca 2ϩ (PerkinElmer). For the response to AITC, the culture media was aspirated, and the cells were incubated with compound 43 or 44 in the assay buffer (F-12 medium supplemented with BSA, 0.1 mg/ml, and 15 mM HEPES) at room temperature for 3 min before and 3 min after the addition of AITC at EC 90 (80 M). To measure the response to cold, cells were incubated with compound 43 or 44 in the assay buffer for 3 min at room temperature. Thereafter, 45 Ca 2ϩ was added, and the plates were left on an EchoTherm chilling platform (Torrey Pines) for 12 min to reach the temperature of 7°C. The plates were washed twice with PBS, and the results were read on TopCount. Compound activity was analyzed using Prism 4.01 (GraphPad Software).
Nocifensive response in mice. Before experiments, mice were habituated to the experimental conditions for 1 h. Mustard oil (0.75%, 20 l), which is often used to assess TRPA1-mediated pain (Jordt et al., 2004; Kwan et al., 2006) , was injected into the right hindpaw. Paw-licking and lifting events were timed for 5 min by an observer blind to the animals' genotype.
Nocifensive response in rats. Before experiments, rats were habituated to the experimental room (30 min) and to Plexiglas observation cylinders (additional 30 min). The cylinders were placed on a custom apparatus in a way that rats could not see each other. Compound 43 (10, 30, or 100 mg/kg), compound 44 (100 mg/kg), or their vehicle was administered by gastric gavage 1 h before the injection of AITC (0.01%, 25 l) into the left hindpaw. The AITC dose was chosen based on an in-house (Amgen) dose-response curve and corresponded to a dose between ED 50 and ED 80 . The number of hindpaw flinches was counted for 1 min by an observer blind to the experimental treatment.
Cold-defense responses in mice. Each mouse was placed in a confiner and equipped with copper-constantan thermocouples (Omega Engineering) to measure colonic T b and tail skin temperature (T sk ). The colonic thermocouple was introduced 2 cm beyond the anal sphincter and secured in the base of the tail with adhesive tape. The skin thermocouple was fixed to the lateral surface of the tail at the borderline between the proximal and middle thirds with a loop of tape, which also insulated the thermocouple from the environment. A similar method was used to record thermoregulatory responses of mice to cold in our recent study (Garami et al., 2011) . The mouse in its confiner was transferred to a Plexiglas chamber of the four-chamber open-circuit calorimeter integrated system (Oxymax Equal Flow, Columbus Instruments). The chamber was sealed, submerged into a temperature-controlled (30°C) water bath, and continuously ventilated with room air (200 ml/min). The fractional concentration of oxygen was measured in the air entering and exiting the chamber, and the rate of oxygen consumption was calculated according to the manufacturer's instructions using the Oxymax Windows software (version 3.1). Cold exposure was achieved by transferring the chamber from the 30°C water bath to an 8°C water bath.
Cold-defense responses in rats. On the day of the experiment, rats in their home cages were placed inside a climatic chamber (model 3940, Forma Scientific) set to a neutral T a of 28°C (Romanovsky et al., 2002) . The animals were allowed to habituate to the experimental conditions for 1 h. Thereafter, the T a in the chamber was increased to 30°C, which is in the upper portion of the thermoneutral zone in this setup (warm environment); under these conditions, tail skin is vasodilated (Romanovsky et al., 2002) . Compound 43, A967079, or AMG2850 (each at 30 mg/kg) or their vehicle was administered as gastric gavage (10 ml/kg) using disposable soft feeding needles. Each rat was then placed in a confiner and equipped with copper-constantan thermocouples (Omega Engineering) to measure deep T b (colonic) and tail T sk . As in other studies from our laboratory (Steiner et al., 2007; Steiner et al., 2011; Almeida et al., 2012), the colonic thermocouple was inserted 10 cm beyond the anal sphincter and fixed to the base of the tail with a loop of adhesive tape. The skin thermocouple was positioned on the lateral surface of the tail (at the boundary of the proximal and middle thirds) and insulated from the environment with tape. Thermocouples were plugged into a data logger (Cole-Parmer). The rats in their confiners were returned to the 30°C chamber and left there for 30 min to allow the administered compound to circulate through the skin . Thereafter, the rats in their confiners were transferred to another chamber set to either 3°C (cold exposure) or 30°C (control).
Plasma concentrations of compound 43 and A967079. At the end of the cold-defense test in rats, their exposure to TRPA1 antagonists was verified. Those rats that were treated with compound 43, A967079, or their vehicle were anesthetized with ketamine-xylazine-acepromazine mixture (55.6, 5.5, and 1.1 mg/kg, i.p.), and cardiac blood was collected in Vacutainer tubes containing lithium heparin (compound 43) or EDTA (A967079). The tubes were centrifuged (1200 ϫ g, 10 min) at 4°C. The plasma was transferred to cryogenic vials, shipped on dry ice to Amgen (compound 43) or AbbVie (A967079), and stored at Ϫ80°C. Concentrations of compound 43 and A967079 were measured by sensitive LC-MS/MS methods optimized for each compound according to the standard Amgen and AbbVie protocols.
Data processing and analysis. Data on colonic T b , tail T sk , and oxygen consumption were compared by factorial (two-way) ANOVA followed by Tukey's honestly significant difference post hoc tests, as appropriate. Numbers of flinches were compared by one-way ANOVA with Dunnett's multiple-comparisons post hoc tests. Data on the nocifensive response duration were compared by Mann-Whitney U test. Plasma concentrations for each compound measured were compared by Student's t test. Statistica AX'99 (Statsoft) and Prism 5.01 (GraphPad) software were used. Data are reported as mean Ϯ SE.
Results
Experiment 1: genetic deletion of Trpa1 does not attenuate cold defenses in mice
To cool mice below the 17°C threshold temperature for TRPA1 activation (Story et al., 2003) , we used a severe cold exposure model (T a of 8°C for 180 min) (Garami et al., 2011) . In this model, both Trpa1 ϩ/ϩ and Trpa1 Ϫ/Ϫ mice developed tail skin vasoconstriction (a decrease in tail T sk ) and cold-induced thermogenesis (an increase in oxygen consumption), but despite these marked cold-defense responses, the deep (colonic) T b temperature decreased precipitously (Fig. 1A) . Neither the deep T b response nor the thermoeffector responses differed between the genotypes. Notably, the tail T sk in both genotypes dropped Ͻ17°C early (ϳ10 min) into the cold exposure. By the end of the experiment, even the colonic T b was ϳ13°C (i.e., 4°C below the TRPA1 activation threshold). Functional TRPA1 deficiency of the knock-out mice used was verified by a 56% reduction in the duration of the paw licking and lifting response to intraplantar mustard oil (12 Ϯ 3 s vs 27 Ϯ 6 s in Trpa1 ϩ/ϩ controls; U (9) ϭ 3.5, Z ϭ Ϫ2.1, p ϭ 3.6 ϫ 10 Ϫ2 ; Fig. 1B ). In summary, the Trpa1 deletion in mice affected neither the deep T b response to severe cold nor the autonomic cold defenses, even though both T sk and deep T b were below the reported threshold temperature for TRPA1 activation. This finding is in agreement with studies showing that Trpa1 Ϫ/Ϫ mice have no deficit in the detection of noxious cold Kwan et al., 2009; Knowlton et al., 2010) . Either TRPA1 channels are not activated by cold in mice or they are not wired to convey temperature signals to autonomic thermoeffectors, or both. A caveat to this interpretation, however, is that Trpa1 Ϫ/Ϫ mice could have developed chronic compensatory upregulation of other cold sensors, which, in turn, could have become functionally important in the absence of TRPA1. To avoid chronic compensation, we decided to use genetically unaltered animals and to block their TRPA1 channels acutely by a pharmacological antagonist, either A967079 (Chen et al., 2011 ) or compound 43 (Gijsen et al., 2012 . Data on selectivity, potency, bioavailability, and efficacy of A967079 were reported by Chen et al. (2011) , but only limited information about compound 43 was available (Gijsen et al., 2012) . Ϫ/Ϫ mice (n ϭ 8), compared with Trpa1 ϩ/ϩ mice (n ϭ 6). The T b dynamics did not differ between the genotypes. Both the tail skin vasoconstriction response (a decrease in the tail T sk ) and the thermogenic response (an increase in oxygen consumption) in Trpa1 Ϫ/Ϫ mice were no less robust than the responses in Trpa1 ϩ/ϩ mice. B, Functional TRPA1 deficiency of Trpa1 Ϫ/Ϫ mice (n ϭ 6) compared with Trpa1 ϩ/ϩ mice (n ϭ 5) was confirmed by a decreased pain response to intraplantar mustard oil (0.75%, 20 l).
19.2 Ϯ 13.0 nM), whereas compound 44 produced only partial and inconsistent effects, if any ( Fig. 2A) . Similar results were obtained by Gijsen et al. (2012) , who studied the effects of compounds 43 and 44 on the activation of rat and human TRPA1 by a different chemical agonist (but not by cold). Our data show that effects of compound 43 on both chemical and cold activation of TRPA1 are highly sensitive to the molecule's chirality. In our selectivity assay (Lehto et al., 2008) , compound 43 did not inhibit any rat or human TRP channel (other than TRPA1) at 20 M. In vivo, the intragastric administration of compound 43 reduced the number of AITC-induced paw flinches in rats in a dosedependent fashion: by 59 Ϯ 14% at 10 mg/kg, 89 Ϯ 7% at 30 mg/kg, and 98 Ϯ 2% at 100 mg/kg. For the ANOVA, we report F (4,35) ϭ 22.3 and p ϭ 3.2 ϫ 10 Ϫ9 ; post hoc Dunnett's tests showed that each dosing group exhibited less finching than the vehicle group ( p Ͻ 5.0 ϫ 10 2 for all doses). In the same test, compound 44 administered at a high dose (100 mg/kg) showed no target coverage (Fig. 2B) . The demonstrated dependence of the analgesic effect of compound 43 on chirality agrees with the on-target action. We conclude that compound 43 is a highly potent, selective, and bioavailable TRPA1 antagonist that shows analgesic efficacy following gastric administration in rats. , 2013) , as a positive control. Because rats respond to cold with cutaneous vasoconstriction and a drastic reduction in cutaneous blood flow, there was a concern that any compound administered to cold-exposed rats might not reach its targets in the skin. As in the past , we dealt with this concern by using two environmental chambers. Drugs were administered to rats in the first (warm) chamber set to a T a of 30°C (the upper end of thermoneutrality in this setup). At this T a , the skin is vasodilated (Romanovsky et al., 2002) . After rats were left in the warm chamber for 30 min, thus allowing the administered compound to circulate through the skin, they were transferred to the second chamber, which was either cold (set to a very low T a of 3°C) or warm (30°C, control). When the rats were transferred from 30°C to 30°C, no significant dynamics in the parameters studied were observed, and there were no significant differences between the treatment groups in either deep T b or tail T sk (Fig. 3A) . These results confirm the earlier findings that TRPM8 and TRPA1 (Chen et al., 2011) antagonists did not affect thermoregulation at thermoneutrality. When rats were transferred from 30°C to 3°C, different thermoregulatory responses occurred in different treatment groups. Vehicle-treated rats produced a small transient rise in deep T b followed by a gradual, mild (ϳ0.9°C) decrease (Fig. 3B) . This is not a surprise, as rats defend their deep T b against cold much better than mice (Fig. 1A) and often respond to cold exposure with an initial rise in deep T b (Szekely et al., 2001 ). The vehicletreated rats in our experiment developed rapid cutaneous vasoconstriction, and their tail T sk dropped to ϳ4°C within minutes and remained at this level throughout the experiment. Responses of rats treated with A967079 or compound 43 did not differ statistically from those of vehicle-treated rats (Fig. 3B) . In contrast, rats treated with AMG2850 showed a marked decrease in T b (Ϫ1.8°C, nadir) in response to cold exposure. The ANOVA showed that the effects of both treatment (F (3,594) ϭ 216.1, p Ͻ 1.0 ϫ 10 Ϫ17 ) and time (F (21,594) ϭ 29.1, p Ͻ 1.0 ϫ 10 Ϫ17 ) were significant, and so was the treatment ϫ time interaction (F (63,594) ϭ 1.9, p ϭ 8.1 ϫ 10 Ϫ5 ). According to Tukey's honestly significant difference tests, the T b response to AMG2850 differed significantly from the response to A967079, compound 43, or their vehicle ( p Ͻ 7.7 ϫ 10 Ϫ6 ). The significant decrease in T b was observed during 60 -180 min ( p ϭ 3.1 ϫ 10 Ϫ2 ). The T b decrease in AMG2850-treated rats was presumably the result of suppression of the thermogenic response, which would also explain the disappearance of the initial T b rise during cold exposure in these rats ( 3B). The observed suppression of the rats' ability to defend their T b in the cold in the presence of AMG2850 is in agreement with the reported effects of this and other TRPM8 antagonists on deep T b (Knowlton et al., 2010; Almeida et al., 2012; , oxygen consumption , and brown adipose tissue temperature of cold-exposed rats and mice. In view of the negative results with both TRPA1 antagonists tested (Fig. 3 A, B) , it was important to confirm that their systemic levels were sufficient to block a TRPA1-dependent response. At the end of experiments, the plasma concentration of A967079 was 2.2 Ϯ 0.5 M in A967079-treated rats and 0.0 Ϯ 0.0 M in vehicle-treated controls (t (16) ϭ 5.5, p ϭ 4.4 ϫ 10 Ϫ5 ; Figure 3C ). The concentration of compound 43 was 468 Ϯ 86 nM in compound 43-treated rats and 0.0 Ϯ 0.0 nM in vehicle-treated controls (t (14) ϭ 7.2, p ϭ 4.8 ϫ 10 Ϫ6 ; Figure 3C ). Importantly, the blood levels of A967079 and compound 43 at the end of experiments were ϳ7 and 24 times higher, respectively, than their corresponding IC 50 values. These strong exposure data agree with the reported analgesic efficacy of both compounds at the doses used in this study (Chen et al., 2011 and Experiment 2) . In summary, neither of the two potent and selective TRPA1 antagonists tested affected the thermoregulatory response of rats to severe cold.
Discussion
The present study has produced two main findings. First, by using knock-out mice, we showed that the deletion of Trpa1 affected neither the defense of deep T b against cold nor the coldinduced activation of autonomic thermoeffectors (tail skin vasoconstriction and thermogenesis). The severity of the cold exposure in this experiment (deep T b was ϳ13°C by the end of experiment) was probably sufficient to bring all temperatures in the body below the threshold temperature for TRPA1 activation, even if the in vivo threshold differs by a couple of degrees from the 17°C threshold reported in vitro (Story et al., 2003) . This suggests that murine TRPA1 channels do not drive autonomic colddefense effectors. However, our study in knock-out mice did not address the issue of potential structural or functional compensation for the chronic lack of TRPA1 in genetically modified animals. To avoid any such compensation, we used the acute administration of pharmacological TRPA1 antagonists, either compound 43 or A967079, in genetically unaltered rats, and our second main finding was obtained in experiments with these antagonists.
In a paradigm where any chronic compensation was not a concern, we showed that neither compound 43 nor A967079 affected the T b response of rats to cold exposure. This suggests that the thermoregulation system does not use TRPA1-dependent temperature signals, at least not in the rat. To make this conclusion definitive, we took multiple methodological precautions and ruled out several alternative interpretations. First, we used two chemically unrelated TRPA1 antagonists (one of which, compound 43, was also characterized in the present study). Second, the dose selected for either antagonist (30 mg/kg, i.g.) has been demonstrated to be efficacious in blocking TRPA1-dependent pain responses in the same species (Chen et al., 2011; present study) . Third, because of cutaneous vasoconstriction in the cold, compounds that are normally efficacious may not reach their targets in the skin during cold exposure . To avoid this pitfall, we administered TRPA1 antagonists in a warm environment, in which cutaneous vasodilation was present and confirmed by a high T sk . Only after the compounds were allowed to circulate through the skin for 30 min were the Figure 3 . Pharmacological blockade of TRPA1 does not affect autonomic cold defenses in rats. A, Compared with their vehicle (n ϭ 6), neither the TRPA1 antagonists compound 43 (n ϭ 13) and A967079 (n ϭ 5) nor the TRPM8 antagonist AMG2850 (n ϭ 13) affected the dynamics of deep T b or tailT sk inratsinthewarmth.Attime0,theratsweretransferredfromoneenvironmentalchamberset to 30°C to a second chamber, which was also set to 30°C (see Materials and Methods). All compounds were administered at the same dose (30 mg/kg, i.g.) 30 min before switching the chambers. B, Compared with their vehicle (n ϭ 11), the TRPA1 antagonists compound 43 (n ϭ 6) and A967079 (n ϭ 8), but not the TRPM8 antagonist AMG2850 (n ϭ 6), had no effect on either the deep T b response to cold or cold-induced vasoconstriction (a decrease in the tail T sk ). At time 0, the rats were transferred from 30°C to 3°C. All compounds were administered at the same dose (30 mg/kg, i.g.) 30 minbeforethetransfer.C,Ratstreatedwithcompound43orA967079,butnotwiththeirvehicle,had a high concentration of the respective compound in their blood plasma at 3.5 h after compound administration. B, C, Results were obtained from the same rats.
animals exposed to the cold. Fourth, we also directly measured both compounds in blood plasma and found that, even at the end of the experiment, each TRPA1 antagonist was still present at a concentration that exceeded its IC 50 value by an order of magnitude. Fifth, we monitored the T sk and confirmed that, at least in the tail, it was substantially (by ϳ13°C) below the 17°C threshold temperature for TRPA1 activation throughout the experiment. Last but not least, we have demonstrated that our methodological design was adequate to reveal a deficit in the detection of cutaneous temperature signals used by the thermoregulation system. When we blocked TRPM8 channels, cold-sensitive channels (for review, see Latorre et al., 2011 ) that function as sensors of skin temperature signals driving autonomic and behavioral thermoeffectors , with AMG2850, an efficacious TRPM8 antagonist Liu et al., 2013) , rats were unable to maintain their deep T b in the cold in our setup. Hence, our conclusion that shell temperature sensors that serve thermoregulation in rodents do not include TRPA1 has strong grounds.
One can still argue that deep T b in our experiments with TRPA1 antagonists did not reach the threshold level for TRPA1 activation and that our experiments do not rule out the possibility that TRPA1 channels serve as core T b sensors for the thermoregulation system, as proposed by Fajardo et al. (2008) . Although we did not test this hypothesis in the experiment with pharmacological blockade of TRPA1 in rats, our experiments with genetic deletion of Trpa1 in mice (in which deep T b was below the TRPA1 activation threshold) argue against it. Furthermore, peripheral thermosensors (that are predominantly cold sensors) are well known to be more important for cold defenses than central sensors (that are predominantly warmth sensors) (for review, see Romanovsky, 2007, in press ). Such organization makes sense, as a brief look at Figure 3B shows that the very severe cold exposure (3°C) in rats resulted only in a small change in deep T b (tenths of a degree), but in a large change in T sk (tens of degrees)-it would be logical to locate cold sensors in the skin. Furthermore, except for special cases (e.g., small animals that readily develop torpor), values of deep T b below the TRPA1 activation threshold are highly unusual for mammals. But even if there were a central cold sensor for such unusual situations, it probably would not be a TRP channel, as electrophysiological effects of temperature on hypothalamic neurons seem incompatible with mediation by TRP channels (Boulant, 2006) . Indeed, several studies have found no difference between temperature-sensitive and insensitive neurons in terms of temperature's effect on resting membrane potentials and currents (Griffin and Boulant, 1995; Zhao and Boulant, 2005) .
A shortcoming of Experiments 1 and 3 was that tail vasoconstriction was assessed by a T sk decrease, which can reflect not only a decrease in the blood flow but also a T a decrease (skin cooling by conduction and convection) or a decrease in the deep T b (and, consequently, in the temperature of arterial blood entering the tail). When T a is constant, the passive cooling effect can be alleviated by calculating the heat loss index (for details, see Romanovsky et al., 2002) . This was not an option in our experiments, in which a deep cold exposure was introduced rapidly. Under these conditions, the vasoconstriction-related portion of the overall decrease in T sk could be hard to reveal (e.g., see Almeida et al., 2012) , and our conclusions about tail vasoconstriction should be taken with a grain of salt. For example, the lack of effect of AMG2850 on the cold-induced vasoconstriction (Fig.  3 ) is in disagreement with the detectable (although small) effect of another TRPM8 antagonist, M8-B, in our earlier study .
It is clear that TRPA1 channels are involved in nocifensive responses to chemical irritants (Nilius et al., 2012) , and our present data, both in vitro and in vivo, support such an involvement. In vitro, we showed that compound 43 blocked AITC-induced activation of rat TRPA1; in vivo, we showed that the same TRPA1 antagonist blocked the pain response of rats to AITC, and also that deletion of the Trpa1 gene in mice attenuated the pain response to mustard oil. There is, however, no consensus as to whether rodent TRPA1 channels serve as cold sensors for nocifensive responses, and, in general, whether TRPA1 channels are (Story et al., 2003; Viswanath et al., 2003; Bandell et al., 2004; Kwan et al., 2006 Kwan et al., , 2009 Klionsky et al., 2007; Fajardo et al., 2008; Andersson et al., 2009; Karashima et al., 2009; del Camino et al., 2010) or are not (Jordt et al., 2004; Nagata et al., 2005; Knowlton et al., 2010; del Camino et al., 2010; Chen et al., 2011; Cordero-Morales et al., 2011) activated by temperature. Doerner et al. (2007) have shown that Ca 2ϩ may directly gate the TRPA1 channel, and Zurborg et al. (2007) proposed that cold activation of TRPA1 is indirect and nonphysiological, and that it occurs in heterologous systems through the increased Ca 2ϩ influx. In defense of the possibility of direct activation by cold, Sawada et al. (2007) performed inside-out singlechannel recordings under Ca 2ϩ -chelating conditions and observed direct activation of TRPA1 by low temperatures. At least two other groups reported cold activation of TRPA1 in Ca 2ϩ -free media (Karashima et al., 2009; del Camino et al., 2010) . Furthermore, at least in insects, there are several isoforms of TRPA1, some of which are thermosensitive (warmthsensitive), whereas others are not (Kang et al., 2011; Zhong et al., 2012) . For example, antennal TRPA1 channels in fruit flies do not play any significant role in the detection of warmth (Gallio et al., 2011) . Zebrafish TRPA1 channels also do not possess a thermosensory function (Prober et al., 2008) .
Even among the mammalian TRPA1 proteins, species differences may further complicate the issue (Chen and Kym, 2009 ). For example, heterologously expressed mouse TRPA1 may be activated by noxious cold (Story et al., 2003; Sawada et al., 2007; Karashima et al., 2009) , whereas human TRPA1 is not (Jordt et al., 2004) . Our study does not shed light on what makes some TRPA1 proteins highly sensitive to temperature. In our in vitro experiments, rat TRPA1 channels in Chinese hamster ovary cells were activated by cold, but whether the observed activation was direct or indirect is unknown.
Even if rat or mouse TRPA1 channel is activated by cold and mediates cold pain, it is still not involved in thermoregulation. From this point of view, the TRPA1 channel is similar to the vanilloid channel TRPV1, which is highly sensitive to temperature, mediates pain responses to noxious heat, but is not involved as a thermosensor in T b regulation, at least not under usual conditions (for review, see Romanovsky et al., 2009 ). TRPV1 and TRPA1 are coexpressed on polymodal nociceptors (Julius, 2013), which are probably not involved in the reception of temperature signals that drive autonomic and behavioral thermoeffectors.
In conclusion, our experiments in mice and rats show that either TRPA1 channels are not activated by cold in vivo, or that they are expressed on cells that are not wired to convey signals to autonomic thermoeffectors, or both. In either scenario, TRPA1 channels in rodents are not used as thermosensors by the thermoregulation system, even during an exposure to severe cold.
